u/lukas_delgado

Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.

What would you do differently, specifically?

the pharmacy and the prescriber are two separate questions

the label on a compounded vial is a legal document, read it

Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.

Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.

log it while it is fresh, memory tidies things up

Was it shipped from a regional warehouse or from origin?

Daily dosing, so what does the exposure profile look like across the day?

the pharmacy and the prescriber are two separate questions

Correction: that domain is one character different from the one you posted, which is rather the point of this thread.

Agreed. Dates and documents make a report. Adjectives make a thread.

do not assume the concentration matches the branded product

Buying small from an unfamiliar supplier and testing before committing is the single procedural change that would have prevented the largest share of

Agreed — and being harder on yourself than you would be on somebody else posting the same thing is the pattern here.

Right, and stopping for money reasons is not a failure of anything. It is a budget.

Correction: that domain is one character different from the one you posted, which is rather the point of this thread.

This. The absence of food and water timing restrictions is the practical difference people will actually notice.

Nothing here is medical advice, and the honest version of most of these posts is that they describe consequences rather than causes.

Small fix — the name you are describing is in the wider-market table with almost nothing on file, not in the documented twenty.

Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.

Push back: daily dosing is not automatically better adherence.

Adding the standing caveat — unapproved, and research material is not for human use.

a lane with four reports is not yet a lane

origin, destination, carrier, month — post all four or the report is noise

Kept the label from every vial.

ruben_cabrera is right about the concentration trap. It breaks arithmetic that has been reliable for months.

Did they name the facility?

summer and winter are different lanes with the same name

a non-peptide agonist does not degrade the way a peptide does

A lane is an origin, a destination, a carrier and a season. Change any one and the distribution changes, which is why supplier-level shipping averages are close to meaningless.

Asked for potency testing on the finished preparation. They had it. I had assumed they would not.

if a clinic will not name the facility, that is your answer

nothing containing this is approved anywhere yet

the boards keep comparing it to injectables at matched doses, which is meaningless

a telehealth intake that asks nothing has told you what it is

I would not read a single slow shipment as a lane change. Post it and let the median move if it is real.

a cloned storefront copies the design, never the documentation

Disagree with naming anyone on that basis. One person’s bad month is not a pattern and the sidebar exists for this exact reason.

Reported something here with dates and screenshots and was asked for the document trail. Fair challenge, and it made the report worth reading.